Quantcast

Latest Rigel Pharmaceuticals Inc. Stories

2010-03-18 06:30:00

SOUTH SAN FRANCISCO, Calif., March 18 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will provide a live webcast for its Investor Day on March 25, 2010 at 10:00am EDT. Members of Rigel's senior management team will provide an overview of the company's current product pipeline. The event will be webcast live and can be accessed from Rigel's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the...

2010-03-17 06:30:00

SOUTH SAN FRANCISCO, Calif., March 17 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Barclays Capital 2010 Global Healthcare Conference in Miami, Florida on Tuesday, March 23 at 10:45 a.m. EDT. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several...

2010-03-05 06:30:00

SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Cowen and Company 30th Annual Health Care Conference in Boston, Massachusetts on Tuesday, March 9th at 3:45 p.m. EST. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website...

2010-03-02 06:00:00

SOUTH SAN FRANCISCO, Calif., March 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2009. For the fourth quarter of 2009, Rigel reported a net loss of $25.1 million, or $0.48 per share, compared to a net loss of $33.4 million, or $0.91 per share, in the fourth quarter of 2008. Weighted average shares outstanding for the fourth quarters of 2009 and 2008 were 51.8 million and 36.6...

2010-02-16 01:01:00

SOUTH SAN FRANCISCO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its senior management team will host a conference call, and simultaneous audio webcast, today at 8:30 a.m. EST (5:30 a.m. PST) to discuss its partnership with AstraZeneca for Rigel's late-stage investigational product, fostamatinib disodium (R788), for the treatment of rheumatoid arthritis and additional indications. Conference Call and Webcast Information To access the...

2010-02-16 01:00:00

SOUTH SAN FRANCISCO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- AstraZeneca and Rigel Pharmaceuticals (Nasdaq: RIGL) today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications. Fostamatinib disodium, which has completed a comprehensive phase 2 program, is the furthest developed oral Spleen Tyrosine Kinase (Syk)...

2010-02-05 06:30:00

SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 12th Annual BIO CEO & Investor Conference in New York City on Monday, February 8th at 10:00 a.m. EST. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several...

2009-12-23 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division. "We believe that ubiquitin ligases represent a promising area of medical...

2009-12-01 06:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that eleven presentations on preclinical studies of the company's product candidates will be given at the upcoming American Society of Hematology (ASH) Meeting and Exposition in New Orleans, Louisiana from December 5-8, 2009. Rigel's R788, an oral Syk kinase inhibitor, will be discussed in two oral presentations by collaborators about its activity in distinct B-cell...

2009-11-03 06:00:00

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2009. For the third quarter of 2009, Rigel reported a net loss of $26.7 million, or $0.70 per share, compared to a net loss of $37.7 million, or $1.03 per share, in the third quarter of 2008. Weighted average shares outstanding for the third quarters of 2009 and 2008 were 38.1 million and 36.6...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.